Abstract
The vesicular monoamine transporter-2 (VMAT2) is considered as a new target for the development of novel therapeutics to treat psychostimulant abuse. Current information on the structure, function and role of VMAT2 in psychostimulant abuse are presented. Lobeline, the major alkaloidal constituent of Lobelia inflata, interacts with nicotinic receptors and with VMAT2. Numerous studies have shown that lobeline inhibits both the neurochemical and behavioral effects of amphetamine in rodents, and behavioral studies demonstrate that lobeline has potential as a pharmacotherapy for psychostimulant abuse. Systematic structural modification of the lobeline molecule is described with the aim of improving selectivity and affinity for VMAT2 over neuronal nicotinic acetylcholine receptors and other neurotransmitter transporters. This has led to the discovery of more potent and selective ligands for VMAT2. In addition, a computational neural network analysis of the affinity of these lobeline analogs for VMAT2 has been carried out, which provides computational models that have predictive value in the rational design of VMAT2 ligands and is also useful in identifying drug candidates from virtual libraries for subsequent synthesis and evaluation.
Keywords: Vesicular monoamine transporter-2(VMAT2), psychostimulant abuse, lobeline, lobeline analogs, computational modeling, nicotinic receptors, neurochemical and behavioral effects of amphetamine, neuronal nicotinic acetylcholine receptors, rational design, in identifying drug candidates, virtual libraries, subsequent synthesis and evaluation, synaptic storage vesicles, DA transport, reduced drug-seeking behavior
Current Topics in Medicinal Chemistry
Title: Design, Synthesis and Interaction at the Vesicular Monoamine Transporter-2 of Lobeline Analogs: Potential Pharmacotherapies for the Treatment of Psychostimulant Abuse
Volume: 11 Issue: 9
Author(s): Peter A. Crooks, Guangrong Zheng, Ashish P. Vartak, John P. Culver, Fang Zheng, David B. Horton and Linda P. Dwoskin
Affiliation:
Keywords: Vesicular monoamine transporter-2(VMAT2), psychostimulant abuse, lobeline, lobeline analogs, computational modeling, nicotinic receptors, neurochemical and behavioral effects of amphetamine, neuronal nicotinic acetylcholine receptors, rational design, in identifying drug candidates, virtual libraries, subsequent synthesis and evaluation, synaptic storage vesicles, DA transport, reduced drug-seeking behavior
Abstract: The vesicular monoamine transporter-2 (VMAT2) is considered as a new target for the development of novel therapeutics to treat psychostimulant abuse. Current information on the structure, function and role of VMAT2 in psychostimulant abuse are presented. Lobeline, the major alkaloidal constituent of Lobelia inflata, interacts with nicotinic receptors and with VMAT2. Numerous studies have shown that lobeline inhibits both the neurochemical and behavioral effects of amphetamine in rodents, and behavioral studies demonstrate that lobeline has potential as a pharmacotherapy for psychostimulant abuse. Systematic structural modification of the lobeline molecule is described with the aim of improving selectivity and affinity for VMAT2 over neuronal nicotinic acetylcholine receptors and other neurotransmitter transporters. This has led to the discovery of more potent and selective ligands for VMAT2. In addition, a computational neural network analysis of the affinity of these lobeline analogs for VMAT2 has been carried out, which provides computational models that have predictive value in the rational design of VMAT2 ligands and is also useful in identifying drug candidates from virtual libraries for subsequent synthesis and evaluation.
Export Options
About this article
Cite this article as:
A. Crooks Peter, Zheng Guangrong, P. Vartak Ashish, P. Culver John, Zheng Fang, B. Horton David and P. Dwoskin Linda, Design, Synthesis and Interaction at the Vesicular Monoamine Transporter-2 of Lobeline Analogs: Potential Pharmacotherapies for the Treatment of Psychostimulant Abuse, Current Topics in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/156802611795371332
DOI https://dx.doi.org/10.2174/156802611795371332 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Editorial [Hot Topic: Relaxin and Related Peptides (Guest Editors: A. Ferlin and C. Foresta)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Radiopharmaceuticals to In Vivo Characterize Adrenal Incidentalomas:The Integrated Role of Radionuclide and Radiological Techniques
Current Radiopharmaceuticals Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics Angiotensin Peptides and Lung Cancer
Current Cancer Drug Targets Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Association of Newly Diagnosed Hypertension and Polypharmacy with Frailty in a Tertiary Hospital Patients from Maracaibo City, Venezuela
Current Hypertension Reviews Efficient Loading and Controlled Release of Benzophenone-3 Entrapped into Self-Assembling Nanogels
Current Nanoscience The Role of Adiponectin in Maintaining Metabolic Homeostasis
Current Diabetes Reviews Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Colon and Rectal Cancer - Novel Biomarkers from Diagnosis to Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets